{"generic":"Belimumab","drugs":["Belimumab","Benlysta"],"mono":{"0":{"id":"jxgas0","title":"Generic Names","mono":"Belimumab"},"1":{"id":"jxgas1","title":"Dosing and Indications","sub":{"0":{"id":"jxgas1b4","title":"Adult Dosing","mono":"<b>Systemic lupus erythematosus, Active, autoantibody-positive, receiving standard therapy:<\/b> 10 mg\/kg IV over 1 hour every 2 weeks for the first 3 doses and every 4 weeks thereafter; consider premedication for potential infusion and hypersensitivity reactions "},"1":{"id":"jxgas1b5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},"3":{"id":"jxgas1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Systemic lupus erythematosus, Active, autoantibody-positive, receiving standard therapy<br\/>"}}},"3":{"id":"jxgas3","title":"Contraindications\/Warnings","sub":[{"id":"jxgas3b9","title":"Contraindications","mono":"anaphylaxis reaction to a previous dose of belimumab <br\/>"},{"id":"jxgas3b10","title":"Precautions","mono":"<ul><li>lupus, severe active nephritis or central nervous system; use is not recommended<\/li><li>concomitant use of IV cyclophosphamide or other biologic therapies, including B-cell targeted therapies; use not recommended<\/li><li>depression, including suicidal ideation and behavior or worsening of depression, have been reported<\/li><li>hypersensitivity reactions, including anaphylaxis and death, have been reported; onset may be delayed; premedication may mask reaction; monitoring recommended; if severe, discontinue therapy immediately and manage medically<\/li><li>infection, chronic; increased risk for developing a serious infection; use not recommended<\/li><li>infections, including serious and fatal cases, have been reported; monitoring recommended; interruption of therapy may be necessary<\/li><li>infusion reactions have been reported; premedication may mask hypersensitivity or infusion reaction; monitoring recommended; slowing or interruption of infusion may be necessary<\/li><li>progressive multifocal leukoencephalopathy (PML) JC virus-associated, including fatalities, has been reported; increased risk with immunosuppressant therapy or impaired immune function; consider PML diagnosis for new onset or worsening neurological manifestations; consider neurologist consultation and discontinue treatment if PML occurs<\/li><li>live vaccine administration; use not recommended within 30 days of belimumab therapy<\/li><li>malignancies have been reported<\/li><li>multiple drug allergies or significant hypersensitivities; increased risk of hypersensitivity reaction<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jxgas3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jxgas3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jxgas5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (12%), Nausea (15%)<\/li><li><b>Immunologic:<\/b>Infectious disease (71%), Infusion reaction (17%)<\/li><li><b>Respiratory:<\/b>Nasopharyngitis (9%)<\/li><li><b>Other:<\/b>Fever (10%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Anaphylaxis (0.6%), Hypersensitivity reaction (13%), Infectious disease, Serious (6%), Infusion reaction, Serious (0.5%)<\/li><li><b>Neurologic:<\/b>Progressive multifocal leukoencephalopathy<\/li><li><b>Psychiatric:<\/b>Depression (5% to 6.3%), Mental disorder (16%)<\/li><li><b>Respiratory:<\/b>Bronchitis (9%)<\/li><li><b>Other:<\/b>Cancer (0.2% to 0.4%)<\/li><\/ul>"},"6":{"id":"jxgas6","title":"Drug Name Info","sub":{"0":{"id":"jxgas6b17","title":"US Trade Names","mono":"Benlysta<br\/>"},"2":{"id":"jxgas6b19","title":"Class","mono":"<ul><li>Immunological Agent<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"jxgas6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jxgas6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jxgas7","title":"Mechanism Of Action","mono":"Belimumab is human IgG1 lambda monoclonal antibody that inhibits the binding of soluble human B lymphocyte stimulator protein (BLyS) to its receptors on the B cells. Belimumab inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells by inhibiting the binding of BLyS to B cells.<br\/>"},"8":{"id":"jxgas8","title":"Pharmacokinetics","sub":{"1":{"id":"jxgas8b24","title":"Distribution","mono":"Vd: 5.29 L <br\/>"},"3":{"id":"jxgas8b26","title":"Excretion","mono":"systemic clearance: 215 mL\/day <br\/>"},"4":{"id":"jxgas8b27","title":"Elimination Half Life","mono":"19. 5 days <br\/>"}}},"9":{"id":"jxgas9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>allow the lyophilized powder vial to stand at room temperature for 10 to 15 minutes<\/li><li>reconstitute with sterile water for injection; swirl the vial gently for 60 seconds every 5 minutes until the powder is dissolved; reconstitution may take up to 30 minutes<\/li><li>dilute the reconstituted belimumab solution to 250 mL in NS<\/li><li>complete the infusion within 8 hours of the start of reconstitution<\/li><li>infuse the diluted solution IV over 1 hour; do not give IV push or IV bolus<\/li><\/ul>"},"10":{"id":"jxgas10","title":"Monitoring","mono":"<ul><li>improvements in objective measures of disease activity indicate a therapeutic response<\/li><li>signs and symptoms of hypersensitivity reactions; during and for several hours after first 2 infusions; during and for appropriate time after subsequent infusions<\/li><\/ul>"},"11":{"id":"jxgas11","title":"How Supplied","mono":"<b>Benlysta<\/b><br\/>Intravenous Powder for Solution: 120 MG, 400 MG<br\/>"},"13":{"id":"jxgas13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid live vaccines for at least 30 days prior and during therapy, due to potential interference with immunization response.<\/li><li>Instruct female patient to avoid pregnancy during therapy and for at least 4 months after the last dose.<\/li><li>Side effects may include nausea, diarrhea, fever, insomnia, migraine, or bronchitis.<\/li><li>Tell patient to report new or worsening neurologic symptoms (ie, memory loss, confusion, dizziness, loss of balance, difficulty walking or talking, or vision changes).<\/li><li>Advise patient to report symptoms of infection or delayed-onset hypersensitivity reactions.<\/li><li>Instruct patient to report new or worsening depression, suicidal ideation, or mood changes.<\/li><\/ul>"}}}